Publications

Authors:

Villacieros-Álvarez, Javier; Espejo, Carmen; Arrambide, Georgina; Dinoto, Alessandro; Mulero, Patricia; Rubio-Flores, Laura; Nieto, Pablo; Alcalá, Carmen; Meca-Lallana, Jose E; Millan-Pascual, Jorge; Martínez-García, Pedro; Bernard-Valnet, Raphael; González-Suárez, Inés; Orviz, Aída; Téllez, Raquel; Navarro Cantó, Laura; Presas-Rodríguez, Silvia; Martínez-Yélamos, Sergio; Cuello, Juan Pablo; Alonso, Ana; Piñar Morales, Raquel; Álvarez Bravo, Gary; Benyahya, Lakhdar; Trouillet-Assant, Sophie; Dyon-Tafan, Virginie; Froment Tilikete, Caroline; Ruet, Aurélie; Bourre, Bertrand; Deschamps, Romain; Papeix, Caroline; Maillart, Elisabeth; Kerschen, Philippe; Ayrignac, Xavier; Rovira, Àlex; Auger, Cristina; Audoin, Bertrand; Montalban, Xavier; Tintore, Mar; Mariotto, Sara; Cobo-Calvo, Alvaro; Marignier, Romain

Title:

Profile and Usefulness of Serum Cytokines to Predict Prognosis in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease

Year:

2025

Type of item:

Articolo in Rivista

Tipologia ANVUR:

Articolo su rivista

Language:

Inglese

Format:

Elettronico

Referee:

Sì

Name of journal:

NEUROLOGY® NEUROIMMUNOLOGY & NEUROINFLAMMATION

ISSN of journal:

2332-7812

N° Volume:

12

Number or Folder:

2

Page numbers:

1-7

Keyword:

myelin oligodendrocyte glycoprotein anti- body–associated disease (MOGAD); pathogenesis; serum cytokines; BAFF

Short description of contents:

Objectives: To characterize the serum cytokine profile in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) at onset and during follow-up and assess their utility for predicting relapses and disability. Methods: This retrospective multicentric cohort study included patients aged 16 years and older meeting MOGAD 2023 criteria, with serum samples collected at baseline (≤3 months from disease onset) and follow-up (≥6 months from the baseline), and age-matched and time to sampling-matched patients with multiple sclerosis (MS). Eleven cytokines were assessed using the ELLA system. Data comparisons and statistical analyses between cytokine levels and clinical outcomes were performed. Results: Eighty-eight patients with MOGAD and 32 patients with MS were included. Patients with MOGAD showed higher IL6 (p = 0.036), IL8 (p = 0.012), and IL18 (p = 0.026) baseline levels compared with those with MS, in non-optic neuritis (ON) presentations. BAFF values increased over time, especially in patients with MOGAD treated with anti-CD20 (p = 0.002). Baseline BAFF, CXCL10, IL10, and IL8 levels correlated with disease severity at MOGAD onset (all p < 0.05). Finally, higher baseline BAFF levels predicted lower risk of relapses (hazard ratio 0.41 [0.19; 0.89], p = 0.024). Discussion: This study suggests a proinflammatory Th17-dominant profile in non-ON MOGAD patients, with a novel finding of a potential protective role of BAFF on relapses. These results shed new light on the pathogenesis of MOGAD, potentially guiding therapeutic decisions.

Web page:

https://doi.org/10.1212/NXI.0000000000200362

Product ID:

143644

Handle IRIS:

11562/1149033

Last Modified:

March 16, 2025

Bibliographic citation:

Villacieros-Álvarez, Javier; Espejo, Carmen; Arrambide, Georgina; Dinoto, Alessandro; Mulero, Patricia; Rubio-Flores, Laura; Nieto, Pablo; Alcalá, Carmen; Meca-Lallana, Jose E; Millan-Pascual, Jorge; Martínez-García, Pedro; Bernard-Valnet, Raphael; González-Suárez, Inés; Orviz, Aída; Téllez, Raquel; Navarro Cantó, Laura; Presas-Rodríguez, Silvia; Martínez-Yélamos, Sergio; Cuello, Juan Pablo; Alonso, Ana; Piñar Morales, Raquel; Álvarez Bravo, Gary; Benyahya, Lakhdar; Trouillet-Assant, Sophie; Dyon-Tafan, Virginie; Froment Tilikete, Caroline; Ruet, Aurélie; Bourre, Bertrand; Deschamps, Romain; Papeix, Caroline; Maillart, Elisabeth; Kerschen, Philippe; Ayrignac, Xavier; Rovira, Àlex; Auger, Cristina; Audoin, Bertrand; Montalban, Xavier; Tintore, Mar; Mariotto, Sara; Cobo-Calvo, Alvaro; Marignier, Romain, Profile and Usefulness of Serum Cytokines to Predict Prognosis in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease «NEUROLOGY® NEUROIMMUNOLOGY & NEUROINFLAMMATION» , vol. 12 , n. 2 , 2025 , pp. 1-7

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo